Abstract. The forkhead transcription factor Foxp3 is essential for differentiation and activation of regulatory T cells (Tregs), and used to be regarded as specific transcription factor of Tregs. In recent years, Foxp3 expression in tumor cells (cancer cell-derived Foxp3) has gained great interest, but its function and molecular mechanisms remain incompletely understood. In the present study, we detected dynamic nuclear translocation of Foxp3 in TSCC cells using immunofluorescent staining. Then we performed a genome-wide analysis of Foxp3 in TSCC cells using a combination of ChIP-on-chip and whole-genome microarray assays. We also compared Foxp3 binding sites in TSCC cells with the known binding sites in human Tregs to show the differences in transcriptional regulation profile. Results indicate that Foxp3 in TSCC cells has distinct biological functions compared with that in Tregs. Cancer cell-derived Foxp3 directly regulates the transcription of genes that affect certain internal biological processes of TSCC cells, and indirectly influences the extracellular microenvironment. This study reveals the relationship between direct and indirect targets genes of Foxp3 in TSCC cells and provide molecular basis of cancer cell-derived Foxp3 function.

Introduction

Regulatory T cells (Tregs) are key players in maintaining immune homeostasis and tolerance. The forkhead transcription factor Foxp3 is essential for differentiation and activation of Tregs (1), and used to be regarded as specific transcription factor of Tregs (2,3). In 2007, Hinz et al (4) first reported that pancreatic cancer cells expressed Foxp3. Subsequent studies reported that breast cancer cells expressed Foxp3, and that Foxp3 positivity was associated with poor prognosis (5). However, other studies reported that Foxp3 acts as a tumor suppressor in breast cancer and prostate cancer (6-8). Thus, the role of Foxp3 expression in cancer cells (referred as ‘cancer cell-derived Foxp3’ in this report) remains incompletely understood, especially regarding molecular mechanisms.

At the molecular level, FOXP3 binds to multiple transcription factors, such as NFAT, NF-κB, STAT3, AML1/Runx1 to regulate T cells function (9-12). It also modulates gene expression through epigenetic mechanisms, such as chromatin remodeling and histone deacetylation (13,14). Zheng et al (15) first performed a genome-wide analysis of Foxp3 in mouse Tregs and found that Foxp3 acts as both a transcriptional activator and repressor in Tregs. Recently, Rudra et al (16) reported that Foxp3 binds to 361 proteins in Tregs and is involved in the transcriptional regulation of most of these proteins. The above demonstrate a complex nature of the interaction of Foxp3 with its target genes. However, less is known about the role of Foxp3 in the transcriptional regulation in cancer cells. In particular, it is unknown whether Foxp3 regulates transcription in cancer cells as it does in Tregs.

Our previous study revealed the expression of Foxp3 in tongue squamous cell carcinoma (TSCC) cells, and showed that the expression of cancer cell-derived Foxp3 was positively associated with the pathologic differentiation and T stage, and inversely associated with overall survival of TSCC patients (17). To achieve further knowledge on these influences, and how cancer cell-derived Foxp3 can regulate TSCC, the present study was performed, using genome-wide analysis of Foxp3 target genes in TSCC cells with a combination of chromatin immunoprecipitation array profiling (ChIP-on-chip assay) and expression profiling (whole-genome microarray assay). We also compared Foxp3 binding sites in TSCC cells with the known binding sites in human Tregs to show the differences in transcriptional regulation profile. This study revealed the relationship between direct and indirect targets genes of Foxp3 in TSCC cells and provide molecular basis of cancer cell-derived Foxp3 function.
Materials and methods

Cell cultures. Three human TSCC cell lines (CAL 27, SCC-9, and SCC-5) were purchased from American Type Culture Collection (ATCC). CAL 27 cells were maintained in DMEM (Gibco, Grand Island, NY, USA) that contained 10% fetal bovine serum (FBS) (Gibco). SCC-9 cells and SCC-5 cells were maintained in DMEM/F-12 (Gibco) that contained 10% FBS.

Cytoimmunofluorescence staining. CAL 27, SCC-9, and SCC-5 cells were seeded into 48-well plates for routine culturing. After washing in PBS, cells were fixed in 4% formaldehyde for 20 min at room temperature, treated with 1% Triton, and then blocked in 5% bovine serum albumin (BSA) at room temperature for 50 min. The cells were then incubated with goat anti-human Foxp3 antibody (10 μg/ml, R&D Systems, Minneapolis, MN, USA) at 4˚C overnight and Northern Lights anti-goat IgG-NSL57 (1:200, R&D Systems) at room temperature in the dark for 1 h. After nuclear staining with 5 μg/ml DAPI for 1 min, cells were observed under an inverted microscope (Axio observer Z1, Zeiss). Negative control was performed by replacing the primary antibody with PBS.

ChIP-on-chip and bioinformatics analysis. SCC-9 cells were seeded into 6-well plates and cultured for 48 h. After washing in PBS twice, 2 ml of fresh medium and 54 μl of 37% formaldehyde were added to each well, followed by incubation at room temperature for 10 min. Then, 200 μl of glycine was added, followed by incubation for 5 min at room temperature. The medium was removed and cells were washed twice with pre-chilled 5 mM EDTA. Then, 200 μl of PBS with 1% PMSF was added to each well, and the cells were harvested. The ChIP-on-chip assay (Shanghai Kangcheng Biotech Co., Ltd., Shanghai, China) was performed with goat polyclonal antibody against FOXP3-ChIP Grade (Abcam, Hong Kong, China) and NimbleGen HG18 3x720K RefSeq promoter microarray (Roche, Mannheim, Germany). The membrane was blocked in Tris-buffered saline (TBST) containing 5% BSA at room temperature for 1 h. After washing in TBST, the membrane was incubated in horseradish peroxidase-conjugated anti-goat IgG (1:10,000; Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)) for 1 h. Each sample was probed with an anti-GAPDH antibody (1:1,000; Santa Cruz) as a loading control.

RNA extraction, reverse transcription and real-time PCR. Total RNA was extracted with the High Pure RNA Isolation kit (Roche) according to the manufacturer’s instructions. RNA (1 μg of each sample) was then used for reverse transcription into cDNA with the Transcriptor First Strand cDNA Synthesis kit (Roche) according to the manufacturer’s instructions. The mRNA expression of Foxp3 was examined by real-time PCR using Light-Cycler 480 SYBR Green I Master (Roche, Mannheim, Germany) and the thermal cycling conditions and primers were the same as described in our earlier study or selected from PrimerBank (17,19). PCRs were conducted in triplicate for each sample. GAPDH was used as internal reference and the 2-△△Ct method was used to determine gene expression.

Human genome-wide expression profiling. After silencing with siRNA for 48 h, RNA in SCC-9 cells was extracted, and the Human Genome U133 plus 2.0 array (Affymetrix, USA) was used for the whole genome array assay. Microarray hybridization was carried out at CapitalBio Corp. (Beijing, China). Cluster analysis was performed with Cluster 3.0 software. Data analysis was performed using Significance Analysis of Microarray software (SAM 3.0, Stanford University, USA; http://www-stat.stanford.edu).

Statistical analysis. Statistical analysis was carried out using SPSS 17.0 statistical software package. Quantitative data analysis employed Student’s t-test to compare two groups and one-way analysis of variance (ANOVA) to compare multiple groups. A P-value <0.05 was considered statistically significant.

Results

Translocation of Foxp3 into nuclei of TSCC cells. Nuclear translocation is essential for transcription factor function, so at first we used immunofluorescent staining to make clear the subcellular distribution of Foxp3 in TSCC cells. After culture of SCC-9 cells for 24 h, the immunofluorescence showed that Foxp3 was present throughout the cells, with the greatest concentration at the nuclear membrane, which appears as a round fluorescent body (Fig. 1A). This expression pattern could also be observed in SCC-15 and CAL 27 cells (Fig. 2). After 48 h, Foxp3 was mainly expressed within the nucleus, and the round body shape of fluorescent staining at the nuclear membrane disappeared (Fig. 1B), indicating that Foxp3 was transported into nucleus gradually.

Next, SCC-9 cells were cultured in DMEM-F12 that contained 0, 5 and 10% FBS for 24 h and then underwent Foxp3 immunofluorescent staining. It can be observed
that cells in the 0% FBS group had a poor growth, and some cells became round and suspended. However, there was Foxp3 expression in the nuclei of cells in all three groups (Fig. 3). This culture assay shows that stimulation from other cell types are not needed in the nucleus translocation of Foxp3 in TSCC cells.

Figure 1. Subcellular translocation of Foxp3 in SCC-9 cells detected by immunofluorescence staining (x400). (A1 and B1) Foxp3 staining; (A2 and B2) Foxp3 staining merged with DAPI staining. When SCC-9 cells were cultured for 24 h, Foxp3 distributed in the whole cell parts, with the greatest concentration at the nuclear membrane, which appeared as a round fluorescent body (A). When SCC-9 were cultured for 48 h, Foxp3 concentrated in nucleus, and the round fluorescent body disappeared, which showed a dynamic nuclear translocation (B).

Figure 2. Subcellular distribution of Foxp3 in CAL27 and SCC-15 cells detected by immunofluorescence staining (x400). (A1 and B1) Foxp3 staining; (A2 and B2) Foxp3 staining merged with DAPI staining. When CAL27 cells (A) and SCC-15 cells (B) were cultured for 24 h, Foxp3 expressed in the whole cell parts, with the greatest concentration at the nuclear membrane.
Foxp3 binding sites and functional annotation in the genome of TSCC cells. The ChIP-on-chip assay identified 4140 binding sites of Foxp3 in the genome of SCC-9 cells [false discovery rate (FDR) <0.05]; after accounting for identical genes, there were 3573 Foxp3-binding genes. Among all genes with FDR values <0.005, there were 25 transcriptional factors: POU3F1, HEY1, TEAD1, POU4F2, VEZF1, KCNIP4, KLF12, E2F1, REST, FOXO4, NR4A1, HOXB8, POU2F1, HOXD9, HIC1, ZBTB16, TCF7, KLF11, IGFBP7, NFIC, PKNOX1, TWIST1, ING1, MEF2A and LITAF.

To reveal general functional features of the molecular program implemented by Foxp3 in TSCC cell, we conducted GO analysis of Foxp3-binding genes. Results showed that the proteins encoded by Foxp3-binding genes mainly located in intracellular parts of TSCC cells (top 10 GO terms - cellular component, Fig. 4A), functioned in transcriptional regulation and biological macromolecule binding (top 10 GO terms - molecular function, Fig. 4B). Biological analysis showed that the proteins encoded by Foxp3-binding genes were involved in many general regulations (top 10 GO terms - biological process, Fig. 4C), and in the top 324 GO terms with P-values <0.001, 131 terms (40.43%) were associated with transcriptional regulation, both upregulation and downregulation. Analysis of our data with the KEGG database indicated that 9 of the top 10 pathways were associated with cancer (Figs. 4D and 5).

Figure 3. SCC-9 cells cultured for 24 h in DMEM-F12 medium with 0, 5 and 10% FBS, respectively. Phase contrast images merged with Foxp3 immunofluorescence staining. Cells in 0% FBS displayed a worse growth, and some cells became round and suspended (A1, red arrows). Cells in 5 and 10% FBS displayed similar normal growth (B and C). Cells in each group had Foxp3 nuclear distribution (A-C).

Figure 4. GO analyses of Foxp3-binding genes in human TSCC cell genome. The top 10 significant GO terms and their enrichment scores was displayed. Cell component analysis showed that the proteins encoded by Foxp3-binding genes mainly located in intracellular parts of TSCC cells (A). Molecular function analysis showed that the proteins encoded by Foxp3-binding genes mainly functioned in transcriptional regulation and biological macromolecule binding (B). Biological analysis showed that the proteins encoded by Foxp3-binding genes were involved in many general regulations (C). Pathway analysis in KEGG database indicated that 9 of the top 10 pathways were associated with cancer (D).
Comparison of Foxp3-binding genes in human TSCC cells and Tregs. We compared the Foxp3-binding genes in human TSCC cells with the known Foxp3 binding sites in human Tregs (18). Previous ChIP-on-chip data showed that 5,579 genes were bound by Foxp3 in Tregs (18). Comparison results showed that 478 Foxp3-binding genes in our ChIP-on-chip data set were also Foxp3-binding genes in human TSCC cells. This overlap corresponds to 12.28% of the Foxp3-binding genes in human TSCC cells and 8.75% of the Foxp3-binding genes in Tregs (Fig. 6).

GO analysis of these 478 overlapped genes showed similar results with the Foxp3-binding genes in human TSCC cells. The encoded proteins were mainly localized on the cell membrane and in the intracellular parts, and functioned in the regulation of transcription and binding to nucleic acids or proteins, including NF-κB (P=4.22x10^-8), but rarely involved in T cell-specific biological processes.

Previous analysis indicated that Foxp3-binding genes in Tregs take part in 86 pathways, most of which are associated with the differentiation, activation, and death of T cells under normal and pathological conditions. However, pathway analysis of overlapped genes also showed similar results with the Foxp3-binding genes in human TSCC cells, and 7 of the top 10 pathways were involved in cancer-related pathways.

Effect of Foxp3 on gene expression in human TSCC cells. Next, we used siRNA to downregulate Foxp3 expression in TSCC cells. In these experiments, SCC-9 cells were transfected with Foxp3 siRNA (Foxp3-si group), control-siRNA (control-si group), or Lipofectamine 2000 (lipo-control group). At 48 h after transfection of SCC-9 cells, Foxp3 expression was downregulated by 85% in the Foxp3-si group relative to the control-si group (P=0.001). There was no
marked difference between control-si and lipo-control groups (Fig. 7).

Then human whole-genome microarray assay showed that there was no significant difference in the gene expression profiles of the control-si group and the lipo-control group, and that the Foxp3-si group was significantly different from the other two groups (Fig. 8A). When the cut-off ratio was set at 2-fold change in expression, 30 genes were upregulated and 36 genes were downregulated in the Foxp3-si group. When the cut-off ratio was set at 1.5-fold change in expression, 269 genes were upregulated and 330 genes were downregulated in the Foxp3-si group. Real-time PCR of 10 randomly selected different-expressed genes was performed to validate the microarray results, as shown in Fig. 8B.

We further performed bioinformatics analysis on these differently expressed genes. Cellular component analysis showed that the proteins encoded by differently expressed genes were mainly distributed in the extracellular parts and the cell membrane (Fig. 9A). Molecular function analysis showed that they were closely related to the cytokine network in that they influenced chemokine activity, growth factor activity, and cytokine activity (Fig. 9B). Analysis of the biological processes showed that the top 10 terms were mainly associated with the regulation of the microenvironment and immunity, such as inflammatory responses, chemotaxis, immune responses, cell-cell signaling, angiogenesis, and neutrophil chemotaxis (Fig. 9C).

Pathway analysis also showed that the proteins encoded by differently expressed genes mainly took part in pathways associated with cytokines and inflammatory reactions, such as cytokine-cytokine receptor interactions, adhesion and diapedesis of lymphocytes, adhesion and diapedesis of granulocytes, molecules involved in local acute inflammatory responses, cytokines and cytokine networks, and inflammatory responses.

**Direct regulation of gene transcription by Foxp3 in TSCC cells.** The ChIP-on-chip and human genome-wide expression profiling assay showed significant difference between the differently expressed genes (after downregulation of Foxp3 expression) and Foxp3-binding genes in TSCC cells. Thus, we tried to reveal the correlation between the data set of ChIP-on-chip and profiling assay to identify genes that are directly regulated by Foxp3. After cross-referencing the data set of Foxp3-binding genes and differently expressed genes, results show that 152 genes (associated genes) were identical in the ChIP-on-chip and expression profiling, with 85 genes being upregulated and 67 genes being downregulated. These associated genes accounted for 4.25% (152/3573) of the Foxp3-binding genes (Fig. 9D) and 25.38% (152/599) of the differently expressed genes (Fig. 9E).

When these associated genes were further analyzed, results showed that the top GO term in cell component was the nucleus. Molecular functions focused on nucleic acid and protein binding, and had little association with the regulation of cytokines. Analysis of biological processes showed that these

---

**Figure 7.** Downregulation of Foxp3 expression in SCC-9 cells using siRNA. Real-time PCR showed Foxp3 mRNA decreased 95%. Western blotting showed Foxp3 protein expression decreased 85.8%.

**Figure 8.** Human genome expression arrays of TSCC cells after Foxp3 RNAi. Cluster analysis showed that comparing to control-si group and lipo-control group, many genes were differently expressed in Foxp3-si group (A). Real-time PCR of 10 randomly selected differently expressed genes validated the microarray results (B).
genes were similar to Foxp3-binding genes in TSCC cells, and that they are extensively involved in different biological processes. Notably, these genes were not specific for the regulation of cytokines, immune responses, inflammatory reactions, and the cellular microenvironment.

Pathway analysis by use of the KEGG database showed that pathways with P-values < 0.001 included adherens junction ($P=4.88 \times 10^{-4}$), ECM-receptor interaction ($P=5.83 \times 10^{-4}$), small cell lung cancer ($P=6.25 \times 10^{-4}$), focal adhesion ($P=6.77 \times 10^{-4}$), and nitrogen metabolism ($P=9.80 \times 10^{-4}$). These results are also similar to those of FOXP3-binding genes in TSCC cells.

**Discussion**

In the present study, we performed a genome-wide analysis of Foxp3 target genes in TSCC cells using a combination of ChIP-on-chip and whole-genome microarray assays. We identified direct and indirect target genes of cancer cell-derived Foxp3 for the first time. Our data suggest that cancer cell-derived Foxp3 directly regulates the transcription of genes that affect certain internal biological processes of TSCC cells, and indirectly influences the extracellular inflammatory microenvironment.

Foxp3 in Tregs is a well-known inducible transcriptional factor. In Tregs, Foxp3 mainly localize in the cytoplasm or adjacent to the nucleus when cells are unstimulated. Upon stimulation with the anti-CD3 or anti-CD28 antibody, Foxp3 undergoes T cell receptor (TCR)-mediated post-transcriptional modification, and within 1 h is translocated into the nucleus (13). However, additional factors may also be needed in Foxp3 translocation after TCR stimulation (20). Moreover, TCR is a specific receptor on the surface of T cells rather than other cell types. Therefore, it is necessary and still difficult to elucidate the mechanism of Foxp3 translocation in tumor cells. Our results showed that Foxp3 expressed in TSCC cells can enter the nucleus, even in the absence of serum. This suggests that cancer cell-derived Foxp3 entry into the nucleus is independent of exogenous stimuli. We speculate that non-microenvironment dependent signal peptide may exist in cancer cell-derived Foxp3, and that factors expressed by TSCC cells themselves may promote Foxp3 translocation into the nucleus, even that TSCC cells can secret factors into microenvironment to induce Foxp3 translocation in Tregs, which can be an exquisite ‘cross-talk’ between tumor cells and lymphocytes. Elucidation of the specific mechanism requires further investigation.
The capability of nucleus translocation of Foxp3 in these cell lines created basic conditions for genome study. We initially speculated that cancer cell-derived Foxp3 may directly regulate the transcription of some extracellular factors, such as cytokines and chemokines, similarly to Foxp3 in Tregs. However, when we used the ChIP-on-chip assay to identify Foxp3 binding sites in the genome of TSCC cells, bioinformatic analysis indicated that proteins encoded by these genes are mainly localized within TSCC cells, and many of these genes are involved in cancer related biological processes. In particular, analysis of molecular function showed that these proteins may bind to multiple proteins, including other transcriptional factors, and this may lead to co-regulation of related genes or alter the levels of free transcriptional factors and thereby affect transcription. Therefore, cancer cell-derived Foxp3 appears to regulate gene transcription through multiple patterns, such as direct regulation, regulation of other transcriptional factors, and regulation of proteins that bind to other transcriptional factors. In the study of Tregs, Rudra et al (16) also showed that, Foxp3 directly binds to genes and regulates the expression of proteins that bind to and regulate Foxp3 itself. This is the first report presenting the DNA binding profile of cancer cell-derived Foxp3. Pathway analysis further showed that the proteins encoded by Foxp3-binding genes are associated with cancer-related pathways.

Sadlon et al (18) performed ChIP-on-chip studies of Foxp3 in human Tregs in 2010 and the genes they identified were distributed in 86 pathways, most of which were associated with the functions and life activities of T cells. In this study, 11 of the pathways that we identified in TSCC cells were also present in Treg cells; four pathways with high enrichment were closely related to cancer. We also compared the Foxp3-binding genes in TSCC cells with those in Treg cells. The results showed that only 478 genes (13.38% of Foxp3-binding genes in TSCC cells) were in both TSCC cells and Tregs. These findings indicate that cancer cell-derived Foxp3 could also directly regulate gene transcription and influence a fraction of biological processes in TSCC cells, and indirectly regulate gene transcription to affect the extracellular inflammatory microenvironment. Further studies such as dual-luciferase reporter gene assay and microenvironment co-cultured model could be used to confirm the mechanism of regulating specific genes by cancer cell-derived Foxp3.

In conclusion, we have, for the first time, identified direct and indirect target genes of cancer cell-derived Foxp3 in TSCC cells. Cancer cell-derived Foxp3 directly regulate the transcription of genes that affect certain internal biological processes of TSCC cells, and indirectly influence the extracellular microenvironment.

Acknowledgements

This study was supported by grants from National Natural Science Foundation of China (nos. 81172566, 81372884 and 81302367), Specialized Research Fund for the Doctoral Program of Higher Education of China (no. 20130171120125), Natural Science Foundation of Guangdong Province (no. S2013040015004).

References

1. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, Macluska KD, Levine SS, Fraenkel E, von Boehmer H and Young RA: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931-935, 2007.
2. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA and Rudensky AY: Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775, 2007.
3. Sakaguchi S: Immunology: Conditional stability of T cells. Nature 468: 41-42, 2010.
4. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grüttmann R, Pilarsky C, Ungefeld H, Saeger HD, et al: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350, 2007.
5. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Ménard S, Tagliabue E and Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27: 1746-1752, 2009.
6. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, et al: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncoprotein. Cell 129: 1275-1286, 2007.
7. Ladoire S, Arnould L, Mignot G, Couderc B, Rêbé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, et al: Expression of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy, Breast Cancer Res Treat 125: 65-72, 2011.
8. Wang L, Liu R, Li W, Chen C, Kaih H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, et al: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16: 336-346, 2009.
9. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, et al: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375-387, 2006.

10. Bettelli E, Dastrange M and Oukka M: Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 102: 5138-5143, 2005.

11. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A and Rudensky AY: CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326: 986-991, 2009.

12. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T and Sakaguchi S: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446: 685-689, 2007.

13. Chen C, Rowell EA, Thomas RM, Hancock WW and Wells AD: Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 281: 36828-36834, 2006.

14. Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, et al: FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 104: 4571-4576, 2007.

15. Zheng Y,Josefowicz SZ, Kas A, Chu TT, Gavin MA and Rudensky AY: Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936-940, 2007.

16. Rudra D, deRoos P, Chaudhry A, Niece RE, Arvey A, Samstein RM, Leslie C, Shaffer SA, Goodlett DR and Rudensky AY: Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol 13: 1010-1019, 2012.

17. Liang YJ, Liu HC, Su YX, Zhang TH, Chu M, Liang LZ and Liao GQ: Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients. Oral Oncol 47: 566-570, 2011.

18. Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, Melville EL, Peng K, D'Andrea RJ, Glonek GG, et al: Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol 185: 1071-1081, 2010.

19. Wang X and Seed B: A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31: e154, 2003.

20. Hancock WW and Ozkaynak E: Three distinct domains contribute to nuclear transport of murine Foxp3. PLoS One 4: e7890, 2009.

21. Medzhitov R: Inflammation 2010: New adventures of an old flame. Cell 140: 771-776, 2010.

22. Cantini G, Pisati F, Mastropietro A, Frattini V, Iwakura Y, Finocchiaro G and Pellegatta S: A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother 60: 1739-1750, 2011.